Isocitrate Dehydrogenase 1 (NADP+), Soluble (IDH1) ELISA Kits

Isocitrate dehydrogenases catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. Additionally we are shipping IDH1 Antibodies (254) and IDH1 Proteins (17) and many more products for this protein.

list all ELISA KIts Gene Name GeneID UniProt
IDH1 3417 O75874
IDH1 15926 O88844
IDH1 24479 P41562
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online
  • orders@antibodies-online.com

Top IDH1 ELISA Kits at antibodies-online.com

Showing 5 out of 29 products:

Catalog No. Reactivity Sensitivity Range Images Quantity Supplier Delivery Price Details
Human 0.33 ng/mL 0.78 ng/mL - 50 ng/mL Typical standard curve 96 Tests Log in to see 12 to 14 Days
$736.84
Details
Rat 1.35 ng/mL 3.12 ng/mL - 200 ng/mL 96 Tests Log in to see 13 to 16 Days
$800.00
Details
Mouse
  96 Tests Log in to see 11 to 18 Days
$589.86
Details
Cow
  96 Tests Log in to see 15 to 18 Days
$1,029.60
Details
Pig
  96 Tests Log in to see 15 to 18 Days
$1,029.60
Details

Top referenced IDH1 ELISA Kits

  1. Human IDH1 ELISA Kit for Sandwich ELISA - ABIN423443 : Tan, Jiang, Sun, Chen, Lv, Shao, Li, Qiu, Gao, Li, Tan, Zhou, Wang, Ding, Wang, Sun, Hang, Shi, Feng, He, He: Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis. in Molecular & cellular proteomics : MCP 2012 (PubMed)
    Show all 3 Pubmed References

  2. Human IDH1 ELISA Kit for Sandwich ELISA - ABIN6574327 : Sun, Chen, Tan, Zhang, Yao, Zhou, Li, Gao, Liu, Tan, Zhou, He, Shao, Li, Qiu, Sun, Yu, Wang, Zhao, Shi, He: Isocitrate dehydrogenase 1 is a novel plasma biomarker for the diagnosis of non-small cell lung cancer. in Clinical cancer research : an official journal of the American Association for Cancer Research 2013 (PubMed)
    Show all 3 Pubmed References

More ELISA Kits for IDH1 Interaction Partners

Human Isocitrate Dehydrogenase 1 (NADP+), Soluble (IDH1) interaction partners

  1. results suggest that there is no impact of IDH mutation status in newly diagnosed FLT3-ITD+ mutated acute myeloid leukemia

  2. IDH1 gene mutations is a complex multi-layered process

  3. Patients with IDH1 mutation and low MCM6 expression exhibited the longest survival

  4. Isocitrate dehydrogenases mutated cases were significantly older but presented with similar rates of advanced-stage disease and sex distribution

  5. clinical prognostication in glioblastoma patients largely depends on classification of IDH mutant and wild type glioblastoma, and not on the presence of IDH1 rs11554137:C>T SNP in the tumor

  6. in intrahepatic cholangiocarcinoma, mutation correlates with a beneficial prognosis and inhibits tumor growth by suppressing Akt signaling

  7. The data show that mutant IDH1 reprogramming of the epigenome and transcriptome is dynamic.

  8. These findings argue against supply of either substrate being limiting for 2-HG production by a cytosolic IDH1 mutant and suggest that the retention of a WT allele in IDH1 mutant tumors is not due to a requirement for carbon or cofactor flux between WT and mutant IDH1.

  9. Our findings revealed that a IDH1(low)/Snail(high) molecular signature could serve as an independent biomarker for poor prognosis in breast cancer.

  10. The present review discusses the molecular basis of the sensitivity of IDH1/2-mutated cancers with respect to the function of mutated IDH1/2 in cellular processes and their interactions with novel IDH1/2-mutant inhibitors. Finally, lessons learned from IDH1/2 mutations for future clinical applications in IDH1/2 wild-type cancers are discussed.[ review]

  11. The data show that 0.3% of prostate cancers have an IDH1R132H mutation and that these are mostly heterogeneous. Once specific anti-IDH1 therapy becomes reality, only a very small group of prostate cancer patients may benefit from such a treatment. Heterogeneity analysis revealed a homogeneous mutation in only 1 of 16 IDH1-mutated cancers. This may profoundly limit therapeutic targeting of IDH1 mutations prostate cancer

  12. IDH mutations may define a unique subset of melanoma patients who are eligible for IDH1 targeted therapies or combined therapies, such as MEK inhibitors when there is co-existing NRAS mutations, or immunotherapy.

  13. Stratification of intrahepatic cholangiocarcinoma patients based on occurrence of mutations in three classifier genes (IDH, KRAS, TP53) revealed unique oncogenic programs (mutational, structural, epimutational) that influence pharmacologic response in drug repositioning protocols.

  14. IDH mutations are more common in preoperative Lower-grade gliomas patients with epileptic symptoms, suggesting that this mutation is positively correlated with seizures.

  15. Heterozygous IDH1(R132H/WT) created by "single base editing" inhibits human astroglial cell growth by downregulating YAP

  16. We found mutations in the IDH1 gene in 34% of the glioma samples, with a predominance of the nonsynonymous mutation R132H

  17. IDH1 or IDH2 mutations play a limited role in the development of ESCC. 2HG is potentially synthesized to high levels in the absence of IDH1 and IDH2 mutations, and this may correlate with progression of ESCCs.

  18. The performance of deep learning based radiomics for predicting the mutation status of isocitrate dehydrogenase 1 (IDH1) was validated in a dataset of 151 patients with low-grade glioma

  19. IDH1 Arg-132 mutation is associated with glioma.

  20. x-ray crystallography of mutant IDH1 binding of an inhibitor (AG-881) to an allosteric site, and compared to IDH2 allosteric site binding

Mouse (Murine) Isocitrate Dehydrogenase 1 (NADP+), Soluble (IDH1) interaction partners

  1. Vitamin C treatment induced an IDH1(R132H)-dependent reduction in cell proliferation.

  2. IDH1 expression regulates TCA cycle in glioma and affects glioma cell growth.GDH2 promotes growth of IDH1-expressing gliomas.

  3. Through the use of a conditional mutant mouse model that confers a less aggressive tumor phenotype, findings provide new insight into the effects of mutant Idh1 on a candidate cell of origin for glioma, mutant Idh1's role in disrupting the microenvironment from which gliomas arise, and mutant Idh1's effect on the course of glioma progression.

  4. IDH1 mutations caused down-regulation of leukocyte chemotaxis, resulting in repression of the tumor-associated immune system.

  5. Idh1(R132H) mutation in the major adult neurogenic stem cell niche causes a phenotype resembling gliomagenesis

  6. Mutant IDH1 downregulates the DNA damage (DD) sensor ATM by altering histone methylation, leading to impaired DNA repair, increased sensitivity to DD, and reduced HSC self-renewal, independent of TET2.

  7. Using whole RNA sequencing of bone marrow cells in iron-overloaded mice, it was observed that Idh1 and Aco1, enzymes involved in the TCA cycle, were elevated.

  8. data suggest that mutant IDH1 contributes to malignancy in the T-cell lineage and may alter the metabolic profile of malignant T cells

  9. The results suggest that Idh1 has a physiological function in protecting cells from oxidative stress by regulating the intracellular NADP(+)/NADPH ratio.

  10. These results support the translational potential of immunotherapeutic targeting of gliomas carrying IDH1 mutations R132H.

  11. MiR-181a regulates lipid metabolism via IDH1

  12. revealed a role for IDH1 in the synthesis/turnover of phospholipids in developing astrocytes and highlight the lipid alterations resulting from the loss of wild-type IDH1 activity.

  13. these data show that mutant IDH or d-2HG causes persistence of chondrocytes, giving rise to rests of growth-plate cells that persist in the bone as enchondromas.

  14. WA might exert its chemopreventive activity via inhibiting not only oncogenic activation, but also IDH1 inactivation.

  15. Brain-specific Idh1-KI mice show brain hemorrhage accompanied by high D2HG levels but decreased ROS

  16. Suggest that decreased IDPc expression renders melanocytes more vulnerable to oxidative stress, and IDPc plays an important antioxidant function in melanocytes.

  17. Absence of IDH1 mutations in low-grade gliomas (LGGs) identifies a novel entity of LGGs with distinctive location, infiltrative behavior, specific molecular alterations, and dismal outcome.

  18. a possible association between IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia.

  19. IDPc would be a major NADPH producer required for fat and cholesterol synthesis.

  20. The results suggest that IDPc plays an important protective role in apoptosis of HL-60 cells induced by singlet oxygen.

Cow (Bovine) Isocitrate Dehydrogenase 1 (NADP+), Soluble (IDH1) interaction partners

  1. Data suggest that the expression of cytosolic NADP+-dependent isocitrate dehydrogenase in bovine mammary epithelium is modulated by regulators of differentiation including extracellular matrix and lactogenic hormones as well as metabolic effectors.

Zebrafish Isocitrate Dehydrogenase 1 (NADP+), Soluble (IDH1) interaction partners

  1. generated a transgenic zebrafish model system for mutations in IDH1 that can be used for functional analysis and drug screening. Our model systems help understand the biology of IDH1 mutations and its role in tumor formation.

IDH1 Antigen Profile

Antigen Summary

Isocitrate dehydrogenases catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. These enzymes belong to two distinct subclasses, one of which utilizes NAD(+) as the electron acceptor and the other NADP(+). Five isocitrate dehydrogenases have been reported: three NAD(+)-dependent isocitrate dehydrogenases, which localize to the mitochondrial matrix, and two NADP(+)-dependent isocitrate dehydrogenases, one of which is mitochondrial and the other predominantly cytosolic. Each NADP(+)-dependent isozyme is a homodimer. The protein encoded by this gene is the NADP(+)-dependent isocitrate dehydrogenase found in the cytoplasm and peroxisomes. It contains the PTS-1 peroxisomal targeting signal sequence. The presence of this enzyme in peroxisomes suggests roles in the regeneration of NADPH for intraperoxisomal reductions, such as the conversion of 2, 4-dienoyl-CoAs to 3-enoyl-CoAs, as well as in peroxisomal reactions that consume 2-oxoglutarate, namely the alpha-hydroxylation of phytanic acid. The cytoplasmic enzyme serves a significant role in cytoplasmic NADPH production.

Gene names and symbols associated with IDH1

  • isocitrate dehydrogenase (NADP(+)) 1, cytosolic (IDH1) antibody
  • isocitrate dehydrogenase 1 (NADP+), soluble (Idh1) antibody
  • isocitrate dehydrogenase (NADP(+)) 1, cytosolic (Idh1) antibody
  • isocitrate dehydrogenase 1 (NADP+) L homeolog (idh1.L) antibody
  • isocitrate dehydrogenase 1 (NADP+), soluble (idh1) antibody
  • AI314845 antibody
  • AI788952 antibody
  • cb876 antibody
  • E030024J03Rik antibody
  • fm90e09 antibody
  • Id-1 antibody
  • IDCD antibody
  • IDH antibody
  • Idh-1 antibody
  • IDP antibody
  • Idpc antibody
  • im:7143416 antibody
  • NADP-CICDH antibody
  • PICD antibody
  • wu:fm90e09 antibody

Protein level used designations for IDH1

NADP(+)-specific ICDH , NADP-dependent isocitrate dehydrogenase, cytosolic , NADP-dependent isocitrate dehydrogenase, peroxisomal , isocitrate dehydrogenase [NADP] cytoplasmic , oxalosuccinate decarboxylase , IDH , IDP , cytosolic NADP-isocitrate dehydrogenase , isocitrate dehydrogenase 1 (NADP+), soluble , isocitrate dehydrogenase [NADP] cytoplasmic-like , Isocitrate dehydrogenase 1, soluble , isocitrate dehydrogenase 1

GENE ID SPECIES
3417 Homo sapiens
443257 Ovis aries
751618 Felis catus
100414768 Callithrix jacchus
15926 Mus musculus
24479 Rattus norvegicus
494713 Xenopus laevis
281235 Bos taurus
100328559 Oryctolagus cuniculus
478889 Canis lupus familiaris
100006589 Danio rerio
100729107 Cavia porcellus
100066416 Equus caballus
Selected quality suppliers for IDH1 (IDH1) ELISA Kits
Did you look for something else?